Ovid Therapeutics
Präsenz
Ovid Therapeutics ist ein Unternehmen, das unter dem Börsenticker OVID (US) gelistet ist.
Führungskräfte
Siehe das Organigramm mit seine 18 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei Ovid Therapeutics
- Jeremy Levin, Chairman of the Board of Directors and Chief Executi...
- Barbara Duncan, Director
- Bart Friedman, Director
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von Ovid Therapeutics nachzuverfolgen.
Biotechnologie
Ovid Therapeutics hat 2.276 Konkurrenten , einschließlich Eurofins (Luxemburg), Lonza (Schweiz) und Adaptive Phage Therapeutics (USA).
Popular M&A news in Biotechnologie
- Histogen has filed for bankruptcy protection (veröffentlicht am 19, April 2024).
- Bruker has announced the acquisition of NanoString Technologies (veröffentlicht am 18, April 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (veröffentlicht am 16, April 2024).
Andere vorgeschlagene Kontakte der Biotechnologie branche
Nachrichten
Neueste Pressemitteilungen nach Ovid Therapeutics
- Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual Congress | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference | Ovid Therapeutics Inc.Email-press-release
- Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020 | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome | Ovid Therapeutics Inc.Email-press-release
- Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe | Ovid Therapeutics Inc.Email-press-release
- View more press releases Close
Social media about Ovid Therapeutics
- Ovid Therapeutics auf Wikipedia, Google News & Yahoo Finance
- Ovid Therapeutics auf LinkedIn, Twitter & YouTube
In Kontakt kommen
Jetzt seine Führungskräfte, darunter auch Kevin Fitzgerald, per E-Mail kontaktieren. 
Ovid Therapeutics unter +1 212... anrufen
